Pubertal development of transfusion-dependent thalassemia patients in the era of oral chelation with deferasirox: results from the French registry

Haematologica. 2024 Jul 1;109(7):2271-2276. doi: 10.3324/haematol.2023.283610.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adolescent
  • Blood Transfusion
  • Chelation Therapy
  • Child
  • Deferasirox* / administration & dosage
  • Deferasirox* / therapeutic use
  • Female
  • France / epidemiology
  • Humans
  • Iron Chelating Agents* / administration & dosage
  • Iron Chelating Agents* / therapeutic use
  • Male
  • Puberty / drug effects
  • Registries*
  • Thalassemia* / therapy
  • Triazoles / administration & dosage
  • Triazoles / therapeutic use

Substances

  • Deferasirox
  • Iron Chelating Agents
  • Triazoles

Grants and funding

Funding: This study did not benefit from any specific funding. The National NaThalY Registry receives fundings from the National Network for constitutional diseases of red blood cells and erythropoiesis (filière MCGRE) and from private pharmaceutical companies.